Ardelyx reports Q3 2026 product revenue of $125.5M, up 19% year over year
FROM THE WIRE · GLOBENEWSWIRE.COM
Q3 2026 total product revenue of $125.5 million , reflecting 19% growth year-over-year IBSRELA Q3 2026 revenue growth of 23% year-over-year to $96.3 million Strong financial position with $285.3 million in cash, cash equivalents and investments as of September 30, 2026…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong revenue growth and a solid cash position are positive factors for the biotech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Q3 2026 total product revenue was $125.5 million, up 19% year over year.
- 02IBSRELA Q3 2026 revenue grew 23% year over year to $96.3 million.
- 03Cash, equivalents and investments were $285.3 million, and Phase 3 CIC enrollment was completed ahead of schedule.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets